Hope no Kejriwal will emerge from my movement again: Anna Hazare

Srinagar, Mar 25: A 65-year-old man hailing from Hyderpora area of the city died on Thursday, becoming the first fatality in Jammu and Kashmir due to coronavirus.
"As we share the sad news of our first #Covid19 fatality, my heart goes out to the family of the deceased. We stand with you and share your grief," Mayor of Srinagar Junaid Azim Mattu tweeted.
Government spokesperson Rohit Kansal also confirmed the death via Twitter.
"First death due to Coronavirus- 65 years old Male from Hyderpora Srinagar. Four of his contacts also tested positive yesterday," Kansal said.
Four people had tested positive for coronavirus in J-K on Wednesday, taking the total number of cases to 11.
Authorities in Kashmir have expressed apprehensions that the cases could be more than reported in the Valley as a significant number of people appeared to have concealed their travel history.
As per a government bulletin on Wednesday in Jammu and Kashmir, as many as 5,124 travellers and people who came in contact with suspected and positive cases have been put under surveillance.

Among them 3,061 are in home quarantine (including facilities operated by the government), 80 in hospital quarantine and 1,477 in home surveillance.
Restrictions on movement imposed in Kashmir to prevent the spread of coronavirus were tightened on Wednesday.

New Delhi, Feb 5: AIMIM chief Asaduddin Owaisi on Wednesday expressed his suspicion over the government using force to clear the Shaheen Bagh stretch where an agitation has been ongoing for over 50 days against Citizenship Amendment Act (CAA).

While speaking to ANI over the phone, Owaisi was asked that there are indications from the government that after February 8, Shaheen Bagh will be cleared.

In reply, he said, "Might be they will shoot them, they might turn Shaheen Bagh into Jallianwala Bagh. This might happen. BJP minister gave a statement to 'shoot a bullet'. The government must give an answer as (to) who is radicalising."

Further speaking about NPR and NRC, Owaisi said, "Government must give a clear cut answer that till 2024 NRC will not be implemented. Why are they spending Rs 3900 crore for NPR? I feel this way because I was a History student. Hitler during his reign conducted census twice and after that, he pushed the jews in a gas chamber. I don't want our country (to) go in that way."

New Delhi, Jun 25: After the Drug Controller General of India (DCGI) given its approval to manufacture and market the generic version of COVID-19 drug Remdesivir, COVIFOR, Hyderabad-based drugmaker Hetero Limited has delivered the first set of 20,000 vials in two equal lots of 10,000 each across 5 states.

The first batch, which is being marketed under the brand name of COVIFOR, was delivered to Maharashtra, Delhi, Gujarat Tamil Nadu and Hyderabad. Hetero has set a target to produce one lakh vials of the drug in two-three weeks.

The other lot would be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week to meet the emergency requirements.

Managing director of Hetero Healthcare M Srinivasa Reddy said “the launch of Covifor in the country is a milestone in addressing public health emergencies. Through Covifor, we hope to reduce the treatment time of a patient in a hospital thereby reducing the increasing pressure on the medical infrastructure overburdened ue to accelerating COVID-19 infection rates," he said as reported by news agency.

"We are closely working with the government and the medical community to make Covifor quickly accessible to both public and private healthcare settings across the country”, Reddy said.

Covifor is a generic brand of Remdesivir which is used for the treatment of COVID-19 in adults and children hospitalised with strong symptoms of the disease. The Health Ministry had, on June 13, recommended the use of anti-viral drug Remdesivir in moderate stage of COVID-19.

Dr Reddys Laboratories and Hetero are among others which have separately entered into non-exclusive licensing agreements with the original drug-maker Gilead Sciences Inc to register, make and sell the investigational drug Remdesivir in India and other countries.

Remdesivir would be made in the company's formulation facility in Hyderabad, which has been approved by global regulatory authorities such as US Food and Drug Administration (USFDA) and EU, among others, Hetero had earlier said.

The treatment first showed improvement in trials on coronavirus patients and was approved for emergency use in severely ill patients in the United States and South Korea.